ReviewSeminars in immunopathology2026
Effect of the intestinal microbiota on T
Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host-microbe reprogramming, and relapse susceptibility.Frontiers in microbiology · 2026Review
- Gut feelings and sweet teeth: nutritional solutions to the gut damage in inflammatory bowel disease and HIV infection.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract (GI tract). Despite extensive research, its exact pathogenesis remains elusive. However, multiple factors are thought to be involved in the onset and progression of IBD. Aside from genetic risk factors, microbial dysbiosis, environmental cues, defects in the epithelial barrier, as well as a dysregulated intestinal immune response, are critical players driving a vicious cycle, which ultimately results in chronic disease. An orchestrated interaction between the intestinal microbiota and the immune response, especially TH17 cells, is critical for maintaining and re-establishing intestinal homeostasis. Nonetheless, a misguided interaction contributes to the pathogenesis of IBD. Indeed, depending on the microenvironment, intestinal TH17 cells possess dual properties. Either they act to control the inflammatory response, or they acquire pro-inflammatory features promoting the development of intestinal pathology. This context-dependent phenotype of TH17 cells has recently been associated with the microbiota composition, which shapes the inflammatory milieu of the gut. To establish precision immunomodulation as a therapeutic strategy for patients with IBD, it is critical to understand how intestinal microorganisms are involved in actively directing the dichotomous nature of TH17 cells and their cytokine products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.